Analysis of factors influencing urinary 3-IS concentrations
| . | 3-IS median (range) . | P . |
|---|---|---|
| Use of antibiotics | ||
| Gut decontamination: rifaximin vs Cipro/Metro (74/56) | 12.9 (0.0-101.9) vs 5.3 (0.0-40.2) | .008 |
| Systemic antibiotics in case of neutropenic infections before ASCT (55/71): without or with | 13.7 (0.0-63.6) vs 0.3 (0.0-101.9) | <.0001 |
| Conditioning: RIC vs standard (112/19) | 8.4 (0.0-101.9) vs 2.4 (0.0-29.6) | NS |
| NOD2/CARD15 genotype: wild type (104)/risk allele (26) | 9.2 (0.0-101.9) vs 0.6 (0.0-20.9) | .002 |
| Stage of underlying disease: early or intermediate (85)/late (45) | 6.6 (0-63.6) vs 6.9 (0-101.9) | NS |
| Patient age ≤50 y (49)/>50 y (81) | 4.5 (0-59.4) vs 11.9 (0-101.9) | NS |
| . | 3-IS median (range) . | P . |
|---|---|---|
| Use of antibiotics | ||
| Gut decontamination: rifaximin vs Cipro/Metro (74/56) | 12.9 (0.0-101.9) vs 5.3 (0.0-40.2) | .008 |
| Systemic antibiotics in case of neutropenic infections before ASCT (55/71): without or with | 13.7 (0.0-63.6) vs 0.3 (0.0-101.9) | <.0001 |
| Conditioning: RIC vs standard (112/19) | 8.4 (0.0-101.9) vs 2.4 (0.0-29.6) | NS |
| NOD2/CARD15 genotype: wild type (104)/risk allele (26) | 9.2 (0.0-101.9) vs 0.6 (0.0-20.9) | .002 |
| Stage of underlying disease: early or intermediate (85)/late (45) | 6.6 (0-63.6) vs 6.9 (0-101.9) | NS |
| Patient age ≤50 y (49)/>50 y (81) | 4.5 (0-59.4) vs 11.9 (0-101.9) | NS |
Significant differences in urinary 3-IS levels were observed depending on the antibiotics administered for gut decontamination, the use of systemic antibiotics prior to ASCT, and NOD2/CARD15 genotype, respectively. Parentheses indicate number of valid cases; in 4 cases, no data for systemic antibiotic therapy prior to ASCT were available. Significance level <.05.
Cipro/Metro, ciprofloxacin and metronidazole; NS, not significant; RIC, reduced intensity conditioning.